NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

NEIMETH International Pharmaceuticals PLC traces its origins to 1957 with Pfizer's operations in Nigeria, initially importing and later manufacturing pharmaceutical and veterinary products. This long-standing presence evolved significantly in May 1997 when the company transitioned into an independent Nigerian entity through a management buyout, acquiring 60% equity from Pfizer Inc., New York, USA. The new company was named in honor of a former Pfizer executive who supported the Nigerian operations. Headquartered in Lagos, Nigeria, Neimeth is a publicly listed pharmaceutical company dedicated to manufacturing, marketing, and distributing a diverse portfolio of healthcare products. The company's core business encompasses two main segments: pharmaceuticals and animal health. Within its pharmaceutical offerings, Neimeth provides ethical drugs, over-the-counter medications, and general healthcare products, including notable brands like Ciklavit, a herbal extract for sickle cell crisis management, Amlovar, Flucosyd, Homtamin G, and Pancemol. The animal health segment features a range of anthelmintic products and production-enhancing medicaments for poultry and other animals, such as Neimeth Piperazine and Neimycin Chick powder. Neimeth primarily serves the Nigerian market and extends its reach across the Economic Community of West African States (ECOWAS) region, including Ghana, Sierra Leone, Liberia, and The Gambia, distributing its products through a structured network.